Partial and full agonists of A 1 adenosine receptors

Details Partial and full agonists of A 1 adenosine receptors Partial and full agonists of A 1 adenosine receptors

2006-11-15

2010-02-02

McIntosh, III, Traviss C (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S263100

Reexamination Certificate

active

07655638

ABSTRACT:
Disclosed are novel compounds that are partial and full A1adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.

REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 4326525 (1982-04-01), Swanson et al.
patent: 4902514 (1990-02-01), Barclay et al.
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 6258793 (2001-07-01), Palle et al.
patent: 6946449 (2005-09-01), Elzein et al.
patent: 2003/0050275 (2003-03-01), Elzein et al.
patent: 2003/0216349 (2003-11-01), Belardinelli et al.
patent: 2003/0232783 (2003-12-01), Ibrahim et al.
patent: 2006/0009417 (2006-01-01), Elzein et al.
patent: 0181129 (1986-05-01), None
patent: 116401 (2001-01-01), None
patent: WO 99/24449 (1999-05-01), None
patent: WO 99/24450 (1999-05-01), None
patent: WO 99/24451 (1999-05-01), None
patent: WO 99/67262 (1999-12-01), None
patent: WO 01/40243 (2001-06-01), None
Dhalia et al., “Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands”, Current Topics in Medicinal Chemistry, 2003, 3, 369-385
Van Der Wenden, E. et al: “5'-Substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor” J. Med Chem 1998, 41, pp. 102-108.
Tilburg, E. et al: “N6 5'-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor”, J. Med Chem, 1999, 42, pp. 1393-1400.
Smejkal, R.M. et al: “Muscarinic receptor subtype specificity of 5'(isobutylthio)-adenosine (SIBA) and its analogues”, Gen Pharmac., 1989, 20(3) pp. 385-392.
Brackett L E et al: “Functional Characterization of the A2B Adenosine Receptor in NIH 3T3 Fibroblasts”, Biochemical Pharmacology, Pergamon, Oxford, GB, vol. 47, No. 5, 1994, pp. 801-814 XP000942545, ISSN: 0006-2952 abstract.
Marumoto R et al: “Synthesis and Enzymatic Activity of Adenosine 3' ,5'-Cyclic Phosphate Analogs”, Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan. Tokyo, JP., vol. 27, No. 4, 1979, pp. 990-1003, ISSN: 0009-2363, *chart 3*, p. 992, table 3.
Munro R et al, “Differential expression of adenosine A2A and A2B receptor subtypes of myeloid U937 and THP-1 cells: Adenosine A2B receptor activation selectively stimulates cAMP formation and inhibition of TNFalpha release in THP-1 cells.” Drug Development Research, vol. 44, No. 1, May 1998, pp. 41-47 ISSN: 0272-4391.
Dhalla et al: Antilipolytic Activity of a Novel Partial A(1) Adenosine Receptor Agonist Devoid of Cardiovascular Effects: Comparison with Nicotinic Acid, Journal of Pharmacology and Experimental Therapeutics, vol. 321, No. 1, Apr. 2007, pp. 327-333.
Morrison et al: “Structure-affinity Relationships of 5'-Aromatic Ethers and 5'Aromatic Sulfides as Partial A1 Adenosine Agonists, Potential Supraventricular Anti-Arrthythmic Agents”, Bioorganic & Medicinal Chemitry Letters, vol. 14, No. 14, Jul. 2004, pp. 3793-3797.
Fatholahi et al: “A Novel Partial Agonist of the A(1)-Adenosine Receptor and Evidence of Receptor Homogeneity in Adipocytes”, Journal of Pharmacology and Experimental Therapeutics, vol. 317, No. 2, May 2006, pp. 676-684.
Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA. 17thEd. (1985).
“Modern Pharmaceutics”, Marcel Dekker, Inc. 3rdEd. (G.S. Banker & C.T. Rhodes, Eds.).
Adenosine A2BReceptors as Therapeutic Targets,Drug Dev Res45:198; Feoktistov et al..,Trends Pharmacol Sci19:148-153, Apr. 1998.
B. Lerman and L. BelardinelliCirculation, vol. 83 (1991), p. 1499-1509.
J. C. Shryock and L. Belardinelli,Am. J. Cardiology, vol. 79 (1997) p. 2-10.
E. A. van Schaick et alJ. Pharmacokinetics and Biopharmaceutics, vol. 25 (1997) p. 673-694.
P. StrongClinical Sciencevol. 84 (1993) p. 663-669.
D. Thiebaud et alMetab. Clin. Exp.vol. 31 (1982) p. 1128-1136.
G. Boden et alJ. Clin. Invest.vol. 93 (1994) p. 2438-2446.
P. J. Randle et alLancet(1963) p. 785-789.
L. J. S. Knutsen and T. F. Murray inPurinergic Approaches in Experimental Therapeutics, Eds. K. A. Jacobson and M. F. Jarvis (1997) Wiley-Liss, N. Y., pp. —423-447.
DMCM, H. Klitgaard Eur.J. Pharmacol.(1993) vol. 224 p. 221-228.
G. Zhang et al.Eur. J. Pharmacol.vol. 255 (1994) p. 239-243.
L. J. S. Knutsen inAdenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology;eds. L. Belardinelli and A. Pelleg, Kluwer: Boston, 1995, pp. 479-487.
Knutsen et al (J. Med. Chem.vol. 42 (1999) p. 3463-3477.
R. B. Clark, B. J. Knoll, R. Barber TiPS, vol. 20 (1999) p. 279-286.
K. Kato et. al. J. Org. Chem. 1997, 62, 6833-6841.
Lorenzen et al. European Journal of Pharmacology, 244, (1993) p. 223-230.
Traynor et al. American Society for Pharmacology and Experimental Therapeutics, 47, (1995), p. 848-854.

Affiliated with

Also associated with

Rating

Partial and full agonists of A 1 adenosine receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Partial and full agonists of A 1 adenosine receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Partial and full agonists of A 1 adenosine receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4206622